Profil
Dr. C.
R.
Cory is Global Head-Business Development at biOasis Technologies, Inc.
Dr. Cory was previously employed as Vice President-Business Development by MIGENIX, Inc.
He received his MBA from Wilfrid Laurier University and a doctorate degree from The University of Waterloo.
Ehemalige bekannte Positionen von C. Robert Cory
| Unternehmen | Position | Ende |
|---|---|---|
MIGENIX, Inc.
 MIGENIX, Inc. Pharmaceuticals: MajorHealth Technology MIGENIX, Inc. develops pharmaceutical drugs. It focuses on advancing therapy, improving health, and enriching life by developing and commercializing drugs in the areas of infectious and degenerative diseases. The Company's clinical programs include drug candidates for the treatment of chronic hepatitis C (Phase II), the prevention of catheter-related infections (Phase III), the treatment of neurodegenerative diseases (Phase I/II) and the treatment of acne (Phase II). MIGENIX was founded in 1993 and is headquartered in Vancouver, Canada. | Corporate Officer/Principal | 24.03.2010 |
| BIOASIS TECHNOLOGIES INC. | Corporate Officer/Principal | - |
Ausbildung von C. Robert Cory
| The University of Waterloo | Doctorate Degree |
| Wilfrid Laurier University | Masters Business Admin |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| BIOASIS TECHNOLOGIES INC. | Health Technology |
| Private Unternehmen | 1 |
|---|---|
MIGENIX, Inc.
MIGENIX, Inc. Pharmaceuticals: MajorHealth Technology MIGENIX, Inc. develops pharmaceutical drugs. It focuses on advancing therapy, improving health, and enriching life by developing and commercializing drugs in the areas of infectious and degenerative diseases. The Company's clinical programs include drug candidates for the treatment of chronic hepatitis C (Phase II), the prevention of catheter-related infections (Phase III), the treatment of neurodegenerative diseases (Phase I/II) and the treatment of acne (Phase II). MIGENIX was founded in 1993 and is headquartered in Vancouver, Canada. | Health Technology |